BioSpace News Archive

Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that it will feature its next generation of medical technology at the upcoming American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 7-11, 2023 in Las Vegas.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 337,000 shares of the Company’s common stock to three new employees on March 1, 2023.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced that management will participate in the following upcoming investor conferences.

Impel Pharmaceuticals Inc., a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced that the Company will participate in two upcoming investor conferences in March.

Mersana Therapeutics, Inc. announced that on March 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of restricted stock unit awards to acquire an aggregate of 44,930 shares of its common stock, to four new employees whose employment commenced in February 2023.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 27,550 restricted stock units of Arcutis’ common stock to four newly hired employees.

Amgen will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday, March 8, 2023.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 10,000 shares of common stock.